Member Info for Inkose

As terrible as this Tories government (to us a word somewhat loosely) is, my takeaway from the EU election results is that Labour under JC can not win a GE. At best they would need coalition partners to gain office. In my view this means that the nationalisation threat has been removed. If that is the case then NG is undervalued.
For the sake of balance let me say that IMHO the Conservative Party will not be back in power in my life time.
I will be looking at market opinion before I add to my holdings.

I also have substantial holdings in those companies but have MRK and IBT (and others) (24% in this sector)
MRK because of keytruda and IBT for exposure to new biotech developments. Novo Nordisk because of the "epidemic of type II diabetes sweeping through Asia.

Well it was the sort of thing that was put on the side of the big red bus.

Asperger1:
The posting misleading "information" is in contravention of BB rules.

How so? I was responding to Levis post of 10:07 today.
I do think that in the coming weeks "Bunker Syndrome" will be more common than ever.

Do I detect that you're showing signs of "Bunker Syndrome".

LONDON (Alliance News) - Woodford Patient Capital Trust PLC on Monday said its portfolio company Evofem Inc reported positive results from the phase 3 clinical trial of contraceptive Amphora.

As of the end of October, Evofem represented a 0.4% position in Woodford Patient Capital Trust's portfolio.

The trust said the prevention of pregnancy drug Amphora successfully met its primary endpoint. Evofem believes that Amphora will now enable health care providers to offer patients an effective birth control method that is "non-hormonal, on-demand, and woman-controlled".

The efficacy, safety and subject satisfaction with Amphora was assessed in 1,400 healthy women aged between 18 and 35 years at 112 centres in the US. The study demonstrated that when Amphora is used as directed, the efficacy in which women can have confidence is similar to other frequently used contraceptive methods.

Biotechnology company Evofem intends to submit the Amphora new drug application to the US Food & Drug Administration in the second quarter of 2019. If approved, it plans to commercialise this birth control treatment in January 2020.

MELBOURNE (Alliance News) - BHP Group PLC said Monday it successfully completed the off-market buyback of Australian-listed BHP Group Ltd shares and announced a USD1.02 per share special dividend, both to return money to shareholders from the sale of the miner's US oil assets.

BHP said the final transaction size of AUD7.3 billion, about GBP4.2 billion, has enabled BHP Group Ltd to buy back approximately 265.8 million shares, which represents 8.3% of the issued share capital of BHP Group Ltd and 5.0% of the total issued capital of BHP Group Ltd and BHP Group PLC.

The price for the buyback was set at AUD27.64 per share. The stock was trading at AUD33.53 in Sydney on Monday.

In addition, BHP declared a special dividend of USD1.02 per share, which will be paid to all BHP shareholders as of January 11, 2019.

The special dividend represents the residual USD5.2 billion of net proceeds from BHP's sale of its onshore US assets not returned via the buyback.

Definitely off topic I'll just flag up that I've just increased my holding of International Biotechnology Trust.
Consistent capital growth and it pays a 4% dividend.

The UK market is up 151 points at the time of writing but AVCT has not moved.

I think the the strengthening share price is a "flight to safety" pre Brexit ( which may or May not happen).

LONDON (Alliance News) - AstraZeneca PLC on Monday announced positive results from its diabetes drug study and said the US Food & Drug Administration has accepted regulatory submission for cancer drug Lynparza.

Farxiga, the pharmaceutical company's type-2 diabetes drug, was found to significantly reduce hospitalisation for heart failure or cardiovascular death by 17% versus placebo. This figure comes as a result of Astra's DECLARE-TIMI 58 trial of more than 17,000 patients.

Patients taking Farxiga were also found to have fewer major adverse cardiovascular events, but this was not statistically significant.

"These positive results are clinically relevant to the 425 million people worldwide living with diabetes, of whom those with type-2 diabetes have a two-to-five times greater risk of heart failure along with an increased risk of a heart attack or stroke," said AstraZeneca Vice President Elisabeth Bjork.

"Heart failure survival rates are only 50% after five years from diagnosis, which is why these new findings are so important in broadening our understanding of how to go beyond blood glucose so we may better address this serious and often overlooked cardiovascular complication," Jork added.

In a separate announcement, Astra also said that the FDA has accepted a supplemental new drug application for priority review. If granted approval, this would be the fourth indication for Lynparza in the US.

The supplemental application is for the use of Lynparza as a maintenance therapy in newly-diagnosed patients with BRCA-mutated advanced ovarian cancer. BRCA mutations mean that patients are more likely to develop genetic alterations that could lead to cancer.

If approved, Lynparza's use will be expanded to patients who are have responded to platinum-based chemotherapy, which is the standard treatment in patients with this type of cancer.

The application is based on the results of Astra's phase three SOLO-1 trial, which showed statistically significant and clinically meaningful improvement in progression-free survival over placebo. Risk of disease progression or death in patients was reduced by 70%.

At present, Lynparza has approval in more than 60 countries for the treatment of relapsed ovarian cancer and for a particular kind of breast cancer.

Shares in AstraZeneca were up 1.7% at 6,274.00 pence on Monday morning.

it appears to work for Borgy64. Good luck to him. I know that I won't be trying to copy him.
When it comes to choosing between the tortoise and the hare, I'm with the tortoise.

I found that having a degree in Biochemistry and a PhD in Biophysics of no help in deciphering the gobbledegook that the reference contained.

Sounds to me that Borgy74 is using spread betting / day trading, though I could very easily be wrong.
Both of these options is highly dangerous if you don't know what you are doing. Most amateurs lose a lot of money. I'm certainly not brave enough to do either.

AstraZeneca (AZN) announces positive results from a Phase 3 clinical trial, HARMONIZE, evaluating hyperkalemia med Lokelma (sodium zirconium cyclosilicate) in patients in Japan, Korea, Taiwan and Russia. The data were presented at Kidney Week in San Diego.

Patients who achieved normal blood potassium levels during the first 48 hours with Lokelma were transitioned to the 28-maintenance phase. Those receiving either 5 mg or 10 mg of Lokelma each day maintained normal blood potassium levels during days 8 - 29, representing statistically significant differences compared to placebo.

Lokelma was approved in Europe in March and in the U.S. two months later.

AstraZeneca obtains positive results from its phase 3 study using Lynparza to treat advanced BRCA mutation ovarian cancer patients.

Patients treated with Lynparza were able to reduce their risk of disease progression or death by 70%.

Lynparza is estimated to generate up to $2 billion in revenue by 2023.

Lynparza is also being explored in combination with Avastin in a phase 3 study known as PAOLA-1 for newly diagnosed ovarian cancer patients regardless of BRCA mutation, with data expected by 2nd half 2019.

The info I have today is:
Gross inflow of funds of £11.75bn rose 12%, while net inflows were up 15%
Retention of client funds continued to remain strong at 96%
Group funds under management are up 11% to £100.6bn since the beginning of the year and 17% over the twelve months
Shares trade on 19.4x consensus 2019 earnings and yield 5.6%.

AstraZeneca and partner Merck said results from their phase 3 clinical trial for their ovarian cancer treatment showed a reduction of disease progression or death by 70%. The Solo-1 Phase III trial was carried out to evaluate the efficacy and safety of the company's ovarian cancer treatment Lynparza as maintenance monotherapy compared with placebo, in newly-diagnosed patients with advanced ovarian cancer who had received platinum-based chemotherapy, AstraZeneca said. Results of the trial confirm the statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) for Lynparza compared to placebo, reducing the risk of disease progression or death by 70% At 41 months of follow-up, the median progression-free survival for patients treated with Lynparza was not reached compared to 13.8 months for patients treated with placebo. But of those who had received Lynparza, 60% remained progression-free at 36 months compared to 27% of women in the placebo arm, the company said. 'There is currently a significant unmet need in the treatment of advanced ovarian cancer because 70% of women relapse within the first three years after their initial treatment. The remarkable results of the SOLO-1 trial, which showed that 60% of women with newly-diagnosed, advanced BRCA-mutated ovarian cancer remained progression-free at three years, highlight the potential of Lynparza as a maintenance therapy in the 1st-line setting,' said Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer. 'Women with ovarian cancer are often diagnosed with advanced disease, which unfortunately is associated with poor long-term survival rates. The newly-diagnosed setting is our best opportunity to achieve a sustained remission, since once a patient's ovarian cancer recurs, it is typically incurable,' said Kathleen Moore, Co-Principal Investigator of the SOLO-1 trial and Associate Director for Clinical Research at the Stephenson Cancer Center at the University of Oklahoma, Oklahoma City. 'The SOLO-1 results demonstrate the potential of Lynparza maintenance therapy earlier in the treatment pathway and reinforce the importance of identifying a patient's BRCA mutation status at the time of diagnosis - these results could change the way we treat women with advanced BRCA-mutated ovarian cancer.' Story provided by StockMarketWire.com

The share price is acting as a Brexit (? economy) barometer.